Satellos Bioscience (TSE:MSCL)
TSX:MSCL
Top Page
Satellos Bioscience
(TSX:MSCL)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$16.50
▲(71.88% Upside)
Action:ReiteratedDate:01/24/26
The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.
Positive Factors
Low leverage
No recorded debt reduces bankruptcy and interest-rate risk, giving the company flexibility to prioritize R&D and partnership structures over debt servicing. For an R&D-stage biotech, low leverage is a durable structural strength that preserves strategic optionality for financing programs or collaborations.
Negative Factors
Pre-revenue
Being pre-revenue means the business depends entirely on financing and milestones rather than product cash flows. This structural reality increases execution and commercialization risk, limits visibility into future margins, and makes long-term viability contingent on successful clinical and regulatory outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
No recorded debt reduces bankruptcy and interest-rate risk, giving the company flexibility to prioritize R&D and partnership structures over debt servicing. For an R&D-stage biotech, low leverage is a durable structural strength that preserves strategic optionality for financing programs or collaborations.
Read all positive factors
Satellos Bioscience (MSCL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$152.27M
Dividend YieldN/A
Average Volume (3M)178.54K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth27.53%
CountryCA
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.51
Shares Outstanding15,458,929
10 Day Avg. Volume239,110
30 Day Avg. Volume178,539
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$38.71Price Target Upside303.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.91
Revenue Forecast (FY)N/A
Satellos Bioscience Business Overview & Revenue Model
Company Description
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system whic...
How the Company Makes Money
Satellos Bioscience generates revenue primarily through research and development partnerships, grants, and potential future licensing agreements for its proprietary technologies. The company collaborates with other biopharmaceutical firms and rese...
Satellos Bioscience Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.57K | -20.00K | -8.82M | -3.73M | -119.92K | -48.16K |
| EBITDA | -24.90M | -28.08M | -15.71M | -8.09M | -4.60M | -1.61M |
| Net Income | -23.68M | -28.10M | -15.89M | -11.32M | -15.51M | -1.58M |
Balance Sheet | ||||||
| Total Assets | 37.50M | 73.02M | 44.30M | 6.20M | 12.59M | 1.13M |
| Cash, Cash Equivalents and Short-Term Investments | 34.61M | 69.85M | 39.59M | 1.92M | 4.87M | 717.53K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09M |
| Total Liabilities | 3.50M | 5.16M | 3.62M | 2.83M | 2.10M | 1.31M |
| Stockholders Equity | 34.00M | 67.86M | 40.67M | 3.37M | 10.48M | -183.84K |
Cash Flow | ||||||
| Free Cash Flow | -24.15M | -24.98M | -14.52M | -5.79M | -5.04M | -1.66M |
| Operating Cash Flow | -24.14M | -24.98M | -14.50M | -5.78M | -5.03M | -1.66M |
| Investing Cash Flow | -18.48M | 6.34M | -17.54M | -3.00K | 1.74M | 0.00 |
| Financing Cash Flow | 55.34M | 53.48M | 51.03M | 2.77M | 7.45M | 1.98M |
Satellos Bioscience Technical Analysis
Negative
9.60
Price Trends
14.00
Negative
11.26
Negative
9.47
Positive
Market Momentum
-1.42
Positive
33.53
Neutral
12.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MSCL, the sentiment is Negative. The current price of 9.6 is below the 20-day moving average (MA) of 13.17, below the 50-day MA of 14.00, and above the 200-day MA of 9.47, indicating a neutral trend. The MACD of -1.42 indicates Positive momentum. The RSI at 33.53 is Neutral, neither overbought nor oversold. The STOCH value of 12.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MSCL.
Satellos Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$152.27M | -5.03 | -89.10% | ― | ― | 27.53% | |
44 Neutral | C$130.61M | -55.85 | -66.34% | ― | ― | 59.00% | |
42 Neutral | C$42.61M | -4.40 | -103.51% | ― | ― | 54.74% | |
41 Neutral | C$36.81M | -12.93 | 72.34% | ― | ― | 10.49% |
* Healthcare Sector Average
TSE:MSCL
Satellos Bioscience
9.85
0.25
2.60%
TSE:ARCH
Arch Biopartners
0.55
-1.27
-69.78%
TSE:MDNA
Medicenna Therapeutics Corp
0.62
-0.38
-38.00%
TSE:HBP
Helix BioPharma
1.71
0.91
113.75%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-8.00
-76.19%
TSE:ONCO
Onco-Innovations Ltd.
1.47
-0.23
-13.53%
Satellos Bioscience Corporate Events
Business Operations and StrategyExecutive/Board Changes
Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances
Positive
Jan 29, 2026
Satellos Bioscience has appointed industry veteran Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs, bringing in a leader with a strong track record in steering breakthrough therapies such as Vertex’s cystic fibro...
Business Operations and StrategyDelistings and Listing ChangesStock Split
Satellos Consolidates Shares Ahead of Proposed Nasdaq Listing
Positive
Jan 28, 2026
Satellos Bioscience has completed a one-for-12 consolidation of its common shares, reducing the number of outstanding shares from about 185.5 million to roughly 15.5 million, as part of its effort to meet the share price and other requirements for...
Business Operations and Strategy
Satellos Bioscience to Present at December Investor Conferences
Positive
Nov 25, 2025
Satellos Bioscience Inc. announced its participation in two upcoming investor conferences in December, where it will present and engage in discussions on polypharmacy in DMD and neuromuscular diseases. This participation highlights Satellos’...
Business Operations and Strategy
Satellos Bioscience Unveils Groundbreaking Research in Duchenne Muscular Dystrophy Treatment
Positive
Nov 18, 2025
Satellos Bioscience announced a significant publication in Nature Communications that supports its innovative treatment approach for Duchenne Muscular Dystrophy (DMD). The research, conducted by the Ottawa Hospital Research Institute, reveals that...
Business Operations and StrategyExecutive/Board Changes
Satellos Bioscience Strengthens Leadership and Advances Clinical Trials for DMD Treatment
Positive
Nov 14, 2025
Satellos Bioscience announced the appointment of Mark Nawacki to its Board of Directors, leveraging his extensive experience in pharmaceuticals and corporate development to guide the company’s growth. The company has made significant strides...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.